Rifamycins and isoniazid form the core of TB therapy, targeting RNA polymerase and mycolic acid synthesis. Key points include CYP450 induction, acetylation variability, hepatotoxicity, drug interactions, and pyridoxin...
Open this topic in Core Concepts